Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases

Table 4

Experimental matrix and values of -average and polydispersity (PDI) of buparvaquone nanostructured lipid carriers.

Form	Order	SL : LL	% Tween 80 (w/w)	% Kolliphor P188 (w/w)	-average (nm)	PDI
12	1	2.75	2.00	2.00	263.2	0.198
2	2	4.00	1.00	1.00	323.1	0.252
6	3	4.00	1.00	3.00	257.3	0.214
9	4	2.75	2.00	2.00	266.9	0.194
5	5	1.50	1.00	3.00	234.6	0.154
8	6	4.00	3.00	3.00	243.9	0.228
7	7	1.50	3.00	3.00	217.7	0.210
1	8	1.50	1.00	1.00	286.0	0.193
11	9	2.75	2.00	2.00	261.3	0.224
10	10	2.75	2.00	2.00	259.4	0.207
3	11	1.50	3.00	1.00	239.7	0.179
4	12	4.00	3.00	1.00	265.9	0.190
20	13	2.75	2.00	2.00	251.4	0.192
18	14	2.75	2.00	3.63	234.2	0.193
16	15	2.75	3.63	2.00	240.5	0.220
14	16	4.79	2.00	2.00	277.2	0.212
17	17	2.75	2.00	0.37	289.0	0.178
19	18	2.75	2.00	2.00	261.2	0.198
13	19	0.71	2.00	2.00	224.8	0.162
15	20	2.75	0.37	2.00	268.8	0.157

Form: formulation; order: preparation order; SL : LL: solid and liquid lipid ratio.